严重的哮喘和omalizumab选项。
文章的细节
-
引用
复制到剪贴板 -
米勒连续波,Krishnaswamy N,约翰斯顿C, Krishnaswamy G
严重的哮喘和omalizumab选项。
中国摩尔过敏。2008年5月20日,6:4。doi: 10.1186 / 1476-7961-6-4。
- PubMed ID
-
18489791 (在PubMed]
- 文摘
-
过敏性疾病和哮喘是在全球范围内以惊人的速度增加。现在也认为哮喘是一种慢性气道炎症性疾病。许多患者的炎症过程是由一个免疫球蛋白E (IgE)端依赖的过程。肥大细胞激活和释放介质,以回应过敏原和IgE,结果在一个级联反应,最终在B淋巴细胞,T淋巴细胞、嗜酸性粒细胞、成纤维细胞、平滑肌细胞和内皮细胞激活。这个复杂的细胞相互作用,释放细胞因子,趋化因子,生长因子和炎症改造的航空公司会导致慢性哮喘。发展严重的呼吸道疾病患者的一个子集,可以极其病态的甚至是致命的。虽然许多治疗方法可用于哮喘,这仍然是一个长期和无法治愈的疾病,特点是恶化,住院治疗和相关药物的副作用。Omalizumab是一种慢性哮喘的新选项,可以通过绑定和抑制IgE的影响,从而干扰哮喘级联的一个方面了。这是一个人性化单克隆抗体IgE,已被证明有许多有利影响哮喘。使用omalizumab可能受到药物的成本和一些报告的副反应包括罕见过敏反应的可能性。 When used in selected cases and carefully, omalizumab provides a very important tool in disease management. It has been shown to have additional effects in urticaria, angioedema, latex allergy and food allergy, but the data is limited and the indications far from clear. In addition to decreasing exacerbations, it has a steroid sparing role and hence may decrease adverse effects in some patients on high-dose glucocorticoids. Studies have shown improvement in quality of life measures in asthma following the administration of omalizumab, but the effects on pulmonary function are surprisingly small, suggesting a disconnect between pulmonary function, exacerbations and quality of life. Anaphylaxis may occur rarely with this agent and appropriate precautions have been recommended by the Food and Drug Administration (FDA). As currently practiced and as suggested by the new asthma guidelines, this biological agent is indicated in moderate or severe persistent allergic asthma (steps 5 and 6).
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物